Research Analysts Issue Forecasts for BHC FY2025 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Equities researchers at Zacks Research decreased their FY2025 EPS estimates for Bausch Health Companies in a report released on Monday, January 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.23 per share for the year, down from their prior estimate of $4.28. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

Several other equities research analysts have also recently weighed in on the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Royal Bank of Canada raised their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Stock Up 1.2 %

Shares of NYSE:BHC opened at $7.82 on Thursday. The business’s 50 day moving average is $7.84 and its 200 day moving average is $7.45. The stock has a market cap of $2.83 billion, a P/E ratio of -16.28 and a beta of 0.69. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. The company had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.03 EPS.

Hedge Funds Weigh In On Bausch Health Companies

Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Bausch Health Companies by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock worth $22,063,000 after purchasing an additional 341,936 shares during the last quarter. Maverick Capital Ltd. purchased a new position in Bausch Health Companies during the 2nd quarter worth $1,606,000. The Manufacturers Life Insurance Company grew its stake in Bausch Health Companies by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock worth $1,719,000 after buying an additional 4,944 shares during the last quarter. Mackenzie Financial Corp increased its position in Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after buying an additional 1,252,834 shares in the last quarter. Finally, Clearline Capital LP purchased a new stake in Bausch Health Companies in the second quarter valued at about $6,881,000. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.